Newsletter | November 19, 2026

11.19.26 -- A New Era For Clinical Development For Brazil

OUTSOURCING MODELS

Brazil's Regulatory Transformation: A New Era For Clinical Development

Brazil’s clinical research transformation takes center stage as this new Q&A series opens with Interfarma CEO and former ANVISA director Renato Porto.

Key Health Policy Priorities Shaping The Second Half Of 2026

See late‑2025 policy actions, including international pricing agreements, new payment models, and global regulatory changes, while previewing key themes expected to shape 2026 health policy.

How Phase I Trial Ethics Are Changing For Sponsors

As early efficacy becomes possible in Phase I studies, hope for benefit must be weighed against limited knowledge, reshaping consent language, risk-benefit review, and protocol design for sponsors and IRBs.

What UK Regulatory Changes Mean For Drug Developers And Sponsors

Stay ahead of the evolving UK regulatory landscape and leverage upcoming reforms to accelerate patient access, drive innovation, and strengthen your position in the medicines development market.

Improving Clinical Trial Access To Meet Regulatory And Patient Needs

Learn how to mitigate regulatory risk and improve trial diversity by reducing site burden and leveraging integrated technology to reach U.S. patients in their own communities.

DGOF Readiness Package For Research Institutions

Our DGOF Readiness Package provides a coordinated set of templates that assist you in achieving compliance. It includes an institutional policy, an IRE charter, and a standard operating procedure.

Clinical Trial Regulations

This essential guide walks through mastering the complex landscape of clinical trial regulations, providing a clear, practical breakdown of regulatory timelines, legal obligations, and more.

Driving Safety And Compliance Seamlessly

Whether it’s accelerating market entry with the “FSP Country in a Box” solution or maintaining global compliance through expert oversight, IQVIA empowers organizations with scalable, localized support.

REGULATORY COMPLIANCE

Why Vendor Oversight Breaks Down At Handoffs

Is a vendor handoff really complete once the file is sent? Not quite. Sponsors still need context, ownership, and evidence to keep trials moving.

CMC And Clinical Strategies For Injectable, Oral Peptide Drugs

Advances in peptide drug delivery have opened new opportunities for peptide drug products, with non-parenteral routes of administration — such as oral and nasal — now feasible.

Clinical, Commercial Packaging: Delivering Next-Gen Therapies

See how strategic, agile, and sustainable packaging is transforming drug delivery into a key driver of speed, safety, and patient-centric innovation.

5 Questions That Reveal Whether A Drug Programme Is Built To Succeed

Explore how Question-Based Drug Development helps teams build knowledge, reduce avoidable surprises and make stronger scientific and investment decisions.

First-In-Human Solutions For Small And Large Molecules

Understand how an integrated approach to first-in-human studies can support small and large molecule programs through efficient execution and informed development decisions.

Why Sponsors Are Moving Away From Multi-Vendor Trial Support

Multi-vendor trial models often limit visibility and coordination. Discover how centralized operations can streamline workflows, control costs, and improve stakeholder experiences.

Full Service CRO And Regulatory Partner For Biologics

Advancing biologics from start to finish is highly complex and full of challenges, requiring scientific strategies and implementation.

Oncology Clinical Trial Experts For Complex Trial Design

Complex oncology trials require deep science, regulatory expertise, and coordination. See how integrated teams and adaptive designs speed startup, protect patients, and scale.

Clinical Excellence – From Molecule To Milestone

Ypsomed accelerates clinical progress by reducing barriers across clinical development, enabling earlier study readiness, greater visibility and more informed decisions.

Proven Expertise With Global Solutions For U.S. Biotechs

The success of a biotech drug development program often depends on the relationship it forms with its Clinical Research Organization (CRO) partner.

Connect With Clinical Leader: